Document Detail

Cost-Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel.
MedLine Citation:
PMID:  22411359     Owner:  NLM     Status:  Publisher    
STUDY OBJECTIVE: To estimate the cost-effectiveness of genotype-guided selection of antiplatelet therapy compared with selecting clopidogrel or prasugrel irrespective of genotype. DESIGN: Decision model based on event occurrence in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38. PATIENTS: Simulated cohort of patients with acute coronary syndrome scheduled to undergo percutaneous coronary intervention (PCI), consisting of three arms: those receiving genotype-guided antiplatelet therapy with clopidogrel or prasugrel, those receiving clopidogrel regardless of genotype, and those receiving prasugrel regardless of genotype. MEASUREMENTS AND MAIN RESULTS: All three arms of the model incorporated the probability that patients would experience a cardiovascular event (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke), a bleeding event (major or minor bleeding), or no event while receiving antiplatelet therapy during the 15 months after the scheduled PCI. The cytochrome P450 (CYP) 2C19 genotype determined antiplatelet drug selection in the genotyping group. Cost-effectiveness was expressed as the incremental cost-effectiveness ratio (ICER) for each event avoided in the genotype-guided therapy arm versus the other two arms. Genotype-guided antiplatelet therapy was dominant, or more effective and less costly, when compared with the selection of clopidogrel (ICER -$6760 [95% confidence interval (CI) -$6720 to -$6790]) or prasugrel (ICER -$11,710 [95% CI -$11,480 to -$11,950]) for all patients without regard to genotype. Genotype-guided therapy that included generic clopidogrel was dominant to prasugrel for all patients (ICER -$27,160 [95% CI -$27,890 to -$26,420]). Cost savings were not evident when genotype-guided therapy that included generic clopidogrel was compared with generic clopidogrel for all patients (ICER -$2300 [95% CI $2290 to $2320]). CONCLUSION: Genotype-guided antiplatelet therapy selection may be more cost-effective and may provide more clinical value due to fewer adverse outcomes.
Emily S Reese; C Daniel Mullins; Amber L Beitelshees; Eberechukwu Onukwugha
Related Documents :
8682079 - Adrenergic beta-blocking agents in congestive heart failure due to idiopathic dilated c...
21295489 - Systematic evaluation of the flexible and rigid annuloplasty ring after mitral valve re...
3010349 - Nutrient control of cardiac rate in the infant rat: alpha-adrenergic mechanisms.
22100929 - Effect of right ventricular pacing site on qrs width.
22439969 - Management and outcome of acute coronary syndrome patients in relation to prior history...
22917729 - Culprit only or multivessel percutaneous coronary interventions in patients with st-seg...
15118289 - Usefulness of stress myocardial perfusion imaging for evaluating asymptomatic patients ...
21539429 - Role of patient chronotype on circadian pattern of myocardial infarction: a pilot study.
23628329 - Is coronary artery disease complexity valuable in the prediction of contrast induced ne...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-12
Journal Detail:
Title:  Pharmacotherapy     Volume:  -     ISSN:  1875-9114     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 Pharmacotherapy Publications, Inc.
Schools of Pharmacy, University of Maryland, Baltimore, Maryland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mesotoga prima gen. nov., sp. nov., the first described mesophilic species of the Thermotogales.
Next Document:  [Optimization of energy intake in artificial nutrition: second lecture Jesús Culebras].